These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 7865870)

  • 21. [The use of intravenous valproate].
    Adín J; Arteaga R; Herranz JL; Armijo JA
    Rev Neurol; 1999 Oct 16-31; 29(8):744-53. PubMed ID: 10560111
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Protein C, protein S and other pro- and anticoagulant activities among epileptic children using sodium valproate.
    Ugras M; Yakinci C
    Brain Dev; 2006 Oct; 28(9):549-53. PubMed ID: 16842952
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment with valproate after status epilepticus: effect on neuronal damage, epileptogenesis, and behavioral alterations in rats.
    Brandt C; Gastens AM; Sun Mz; Hausknecht M; Löscher W
    Neuropharmacology; 2006 Sep; 51(4):789-804. PubMed ID: 16806297
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Serum lipids, vitamin B12 and folic acid levels in children receiving long-term valproate therapy.
    Geda G; Caksen H; Içağasioğlu D
    Acta Neurol Belg; 2002 Sep; 102(3):122-6. PubMed ID: 12400250
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety and tolerability of the ketogenic diet in pediatric epilepsy: effects of valproate combination therapy.
    Lyczkowski DA; Pfeifer HH; Ghosh S; Thiele EA
    Epilepsia; 2005 Sep; 46(9):1533-8. PubMed ID: 16146450
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sodium valproate at therapeutic concentrations changes Ca2+ response accompanied with its weak inhibition of protein kinase C in human astrocytoma cells.
    Kurita M; Nishino S; Ohtomo K; Rai M; Shirakawa H; Mashiko H; Niwa S; Nakahata N
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Apr; 31(3):600-4. PubMed ID: 17258372
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Anti-glutamatergic effect of riluzole: comparison with valproic acid.
    Kim JE; Kim DS; Kwak SE; Choi HC; Song HK; Choi SY; Kwon OS; Kim YI; Kang TC
    Neuroscience; 2007 Jun; 147(1):136-45. PubMed ID: 17507170
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacology of valproate.
    Owens MJ; Nemeroff CB
    Psychopharmacol Bull; 2003; 37 Suppl 2():17-24. PubMed ID: 14624230
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of intracerebroventricular continuous infusion of valproic acid versus single i.p. and i.c.v. injections in the amygdala kindling epilepsy model.
    Serralta A; Barcia JA; Ortiz P; Durán C; Hernández ME; Alós M
    Epilepsy Res; 2006 Jul; 70(1):15-26. PubMed ID: 16616829
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A comparison of the effects of valproate and its major active metabolite E-2-en-valproate on single unit activity of substantia nigra pars reticulata neurons in rats.
    Rohlfs A; Rundfeldt C; Koch R; Löscher W
    J Pharmacol Exp Ther; 1996 Jun; 277(3):1305-14. PubMed ID: 8667191
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Insulin-related metabolic changes during treatment with valproate in patients with epilepsy.
    Pylvänen V; Pakarinen A; Knip M; Isojärvi J
    Epilepsy Behav; 2006 May; 8(3):643-8. PubMed ID: 16600693
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pro- and anticoagulatory factors under sodium valproate-therapy in children.
    Banerjea MC; Diener W; Kutschke G; Schneble HJ; Korinthenberg R; Sutor AH
    Neuropediatrics; 2002 Aug; 33(4):215-20. PubMed ID: 12368993
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Distribution of unsaturated metabolites of valproate in human and rat brain--pharmacologic relevance?
    Adkison KD; Ojemann GA; Rapport RL; Dills RL; Shen DD
    Epilepsia; 1995 Aug; 36(8):772-82. PubMed ID: 7635096
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of sodium valproate monotherapy on serum uric acid concentrations in ambulatory epileptic children: a prospective long-term study.
    Attilakos A; Voudris KA; Garoufi A; Mastroyianni S; Dimou S; Prassouli A; Katsarou E
    Eur J Paediatr Neurol; 2006; 10(5-6):237-40. PubMed ID: 17035050
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Sodium valproate, platelet dysfunction and bleeding (author's transl)].
    Loiseau P
    Nouv Presse Med; 1981 Dec; 10(46):3789-90. PubMed ID: 6798554
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Valproate: past, present, and future.
    Johannessen CU; Johannessen SI
    CNS Drug Rev; 2003; 9(2):199-216. PubMed ID: 12847559
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antiepileptic drugs and plasma and platelet taurine in epilepsy.
    Goodman HO; Shihabi Z; Oles KS
    Epilepsia; 1989; 30(2):201-7. PubMed ID: 2494044
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Taurine and epilepsy.
    Oja SS; Saransaari P
    Epilepsy Res; 2013 May; 104(3):187-94. PubMed ID: 23410665
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neurophysiological and biochemical changes evoked by valproic acid in the central nervous system.
    Cotariu D; Zaidman JL; Evans S
    Prog Neurobiol; 1990; 34(4):343-54. PubMed ID: 2110371
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Carnitine disposition before and during valproate therapy in patients with epilepsy.
    Riva R; Albani F; Gobbi G; Santucci M; Baruzzi A
    Epilepsia; 1993; 34(1):184-7. PubMed ID: 8422857
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.